The Consumption of Energy Drink and Its Potential Effect on Sleep Patterns: A Case Study in the Kumasi Metropolis

Background: The availability of energy drinks on the global market result from intensive marketing campaigns in the media. The purpose of this study was to evaluate the consumption of energy drink and its potential effect on sleep patterns of consumers. Methods: A descriptive cross-sectional design with self-administered questionnaire was used for this survey. An online survey using google forms was created for the validated questionnaires after pre-testing and the link shared on different social media platforms. Period of data collection lasted between January and September, 2020. Results: A total of 384 participants were involved in this study. From the study, prevalence of energy drink consumption in the metropolis is 61.5% (n=236). A percentage of 69.1 % (n=163) of the consumers are males relative to 30.9% (n=73) who are females. Results from the study indicate that most patronized energy drink in the metropolis has energy value per 100 ml of 158 kJ with no proteins and fats but an 8.9 g of carbohydrate. The caffeine content of this energy drink is 0.012% and 13% glucose syrup. A total of 29.6% (n=70) of energy drink consumers indicated it to be their preference. Least consumed energy drink (0.85%) has 30-35 mg/100 ml of caffeine with about 192 kJ energy value. Furthermore, results point out that 70.8% (n=167) of the consumers experienced change in sleep pattern. Although other factors may have caused this change in sleep pattern, Pearson Chi-Square result (x2 = 83.277, p≤0.01) reveals that indeed there is association between energy drink consumption and change in sleep pattern as majority of energy drink consumers indicated that they usually experience changes in wake-up time and/or bedtime. Conclusion: The study has demonstrated that majority of the youth in the Kumasi Metropolis consume energy drinks which ultimately causes change in their sleep pattern. This change can alter their daily activities and health status.

Evaluation of Okra Pectin from Different Genotypes as Effective Suspending Agents in Pharmaceutical Formulations

Introduction:  Natural suspending agents are increasingly being investigated because of their relative non-toxicity, lesser cost, availability and biocompatibility compared to the currently utilised synthetic and semi-synthetic suspending agents. Pectin, a biopolymer found naturally in plants is gaining increased application in the pharmaceutical and biotechnology industry following its successful functional application as gelling agents, emulsifying agents and fat substitutes in the food industry. This study aimed at evaluating the suspending properties of pectin obtained from five okra (Abelmoschus esculentus L.) genotypes; PL1 (Penkrumah), PL2 (Agbagoma), PL3 (Asha), PL4 (Sengavi) and PL5 (Balabi). Materials and methods: The pectin was extracted using standard protocols and characterised by investigating properties such as degree of esterification. A 5% w/v paracetamol suspension was formulated utilising okra pectin as a suspending agent at concentrations of 0.5%, 1% and 2%w/v and compared to Tragacanth gum suspensions at the same concentrations (0.5%, 1% and 2%w/v). Results: All the extracted pectins had low degrees of esterification (?50 %). The pH, redispersibility, apparent viscosity, sedimentation rate and sedimentation volume of the formulated suspensions were investigated over a 4-week period. The suspensions were stable as evidenced by no significant (p?0.05) fluctuations in pH during the period of study. Compared to when tragacanth was used as a suspending agent, the sedimentation rates, the flow rates of suspensions and redispersibility of the paracetamol suspensions utilising okra pectin were lower while the sedimentation volumes were higher at all the concentrations utilized and met standard requirements. Conclusion: The evidence suggests that all five okra genotypes exhibit better suspending properties when compared to tragacanth gum and thus may be used as an alternative suspending agent

Induction and abrogation of LACK reactive cells in the evolution of human leishmaniasis

Peripheral blood mononuclear cells (PBMC) from cutaneous leishmaniasis patients with ongoing Leishmania aethiopica infection and individuals cured/under treatment from L. infantum or L. donovani infection were stimulated in vitro with LACK, the Leishmania homologue of receptors for activated C kinase. The LACK protein is conserved in related leishmanial species and is expressed both in the promastigote and amastigote stages of Leishmania. Our results show that LACK induced marked NK and some CD8+ cell proliferation in PBMC from cutaneous leishmaniasis patients with active disease. These responses were coupled with high levels of IFN-γ and IL-10 production. At the concentration tested, the proliferative responses to freeze-thawed Leishmania antigen (Ft-Leish) were higher, while the levels of IFN-γ were consistently lower than that of LACK. Although cells from individuals cured of leishmaniasis could respond to whole Leishmania lysate by proliferation and IFN-γ production, there was no evident response to LACK. Ethiopian controls tested at the same time also showed LACK induced proliferation with IFN-γ and IL-10 responses. Thus LACK reactivity in terms of proliferation and cytokine induction were present in cells from some healthy donors and most of the patients with active lesions, while this response was absent in individuals cured of L. infantum or L. donovani leishmaniasis. Since cure from leishmaniasis often results in life-long protection, and active but not cured patients showed in vitro responses to LACK stimulation, questions arose as to how this highly immunodominant molecule functions during human leishmanisasis. Some possible mechanisms are discussed

Pectin from Okra (Abelmoschus esculentus L.) Has Potential as a Drug Release Modifier in Matrix Tablets

Natural polymers have become attractive to pharmaceutical researchers and manufacturers as excipients because of the advantages they possess relative to their semisynthetic and synthetic counterparts. Although pectin from some natural sources has been investigated for use in the pharmaceutical industry as excipients, pectin from okra, which is readily available and used as food in many parts of the world, has not been extensively investigated as a potential control-releasing agent in tablets. This study thus seeks to determine the drug release modifying properties of okra pectin from 6 different genotypes of okra cultivated and available in Ghana. Pectin was extracted from different genotypes of okra, physicochemical properties were characterized, and control release matrix tablets of metformin (F1–F6) were formulated using the wet granulation method with the okra pectin as the drug release modifier, respectively. The drug content, in vitro drug release, and mathematical kinetic modeling of drug release from the matrix tablets were studied. Drug release profiles of formulated matrix tablets were compared to an existing (innovator) brand of metformin sustained-release tablet on the market using the similarity and difference factors, respectively. The extracted pectin had percentage yields ranging from 6 to 20% w/w with swelling indexes and water-holding capacities between 300–500% and 9-10 mL/g, respectively, and pH within 6.20–6.90. All the formulated batches passed the drug content test (90–105%) and produced the optimal release of metformin (>80%) after 24 hours. Different batches of formulated tablets exhibited different mechanisms of drug release with batches F1, F2, F5, and F6 being similar (ƒ2 values being >50 and ƒ1 values <15) to the innovator brand. Pectin from the 6 different genotypes of okra studied has the potential for use as drug release modifiers in pharmaceutical manufacturing of control release matrix tablets and production of more affordable medicines

Physicochemical and Microbiological Characteristics of Stem Bark Exudate Gum of Cordia millenii Tree in Conventional Release Tablets

The development of a raw material into an acceptable pharmaceutical excipient involves evaluation of the physicochemical and formulation properties of the potential raw material. Results from these evaluations may serve as a guide to subsequent use of the substance. The objective of the study was to evaluate the physicochemical and microbiological properties of the stem bark gum of Cordia millenii tree in conventional release paracetamol tablets. From the physicochemical evaluations, the gum was slightly acidic and soluble in all the aqueous-based solvents, except 0.1 N HCl in which it was sparingly soluble. All the absorptive properties of the gum indicated tablet disintegrating potential for tablet formulation. The total ash of the gum was higher than that of the international standard gum arabic. Micromeritic properties of the gum indicated the need for a flow aid to improve its flowability. There were no harmful microorganisms detected in the gum. Aerobic organisms and moulds and yeast were detected within permissible limits. Tablets formulated using six different concentrations of gum dispersions as a binder were generally soft and failed the USP T80 standard of dissolution, indicating poor binding and drug releasing properties. Quality control properties of three different batches of tablets containing varying concentrations of the dry gum as a disintegrating agent were comparable to tablets containing equal concentrations of corn starch. The in vitro drug releases were similar at all-time points of drug evaluation. The gum can therefore be considered as a good disintegrant in the formulation of conventional release tablets

Alteration of Fas and Fas ligand expression during human visceral leishmaniasis

Several studies in murine systems have suggested a role of apoptosis in the pathogenesis of leishmaniasis. However, the role of apoptosis in visceral leishmaniasis in man has not been explored. In this study, we show that patients with visceral leishmaniasis demonstrate significant dysregulation of Fas and Fas ligand. Levels of soluble Fas (sFas) and soluble Fas ligand (sFasL) were elevated in plasma of patients with active visceral leishmaniasis (VL) and individuals co-infected with VL-HIV-1 compared to healthy controls. The levels of sFas and sFasL were normalized 6 months after successful treatment. In VL patients, the expression of membrane bound Fas, and to a lower extent FasL, were up-regulated on Leishmania donovani-infected spleen cells, the site of parasite multiplication. Expression of Fas and FasL on peripheral blood mononuclear cells was within normal range, probably reflecting that the blood is not a normal site of L. donovani infection. Furthermore, this is suggested by the finding that in vitro infection of macrophages with L. donovani up-regulated Fas expression on the surface of infected cells and enhanced the levels of sFasL in supernatants from infected cultures. How this dysregulation may affect the pathogenesis of human visceral leishmaniasis is discussed